In the Asia & Oceania region, this product was launched in South Korea in October 2013. 

Additional indication applications were submitted in the U.S. in March 2014 and in Europe the following month for the treatment of men with metastatic castration-resistant prostate cancer who have not received chemotherapy. 

Enzalutamide is a once-daily oral androgen receptor signaling inhibitor, which is being developed jointly with Medivation, Inc. (“Medivation”). In the U.S., Astellas and Medivation co-promote XTANDI and share costs and  profits equally. In all countries excluding the U.S., Astellas will develop and sell XTANDI, while paying Medivation  royalties based on sales. 

* The following precaution has been issued regarding indication: the efficacy and safety of the drug have not been established in patients with prostate cancer who have not received chemotherapy. 

## Sales of Mainstay Products by Geographical Area 

One of the features of Astellas is the large number of dis- tinctive products offered in each region, in addition to the global products mentioned above. Growth in sales of these products also contributes to consolidated sales. 

## Japan 

## Micardis (Hypertension treatment) Micombi (Combination drug with a diuretic) Micamlo (Combination drug with a long-acting calcium antagonist) 

Sales of drugs in the Micardis product line, including Micombi and Micamlo, increased by 8.9%, to ¥97.6 billion. Sales continued to grow favorably for Micamlo, a combina- tion drug with a calcium antagonist. In fiscal 2013, the market for angiotensin II receptor blockers (ARB) in Japan expanded 3.2%, to around ¥610.0 billion. Steady expan- sion in sales of the Micardis line of drugs contributed to its current ARB market share of around 18% (on a value basis). Furthermore in May 2013, “Micamlo Combination Tablets BP” was newly launched. In Japan, Astellas is co-promoting the Micardis product line with Nippon Boehringer Ingelheim Co., Ltd. 

## Celecox (Anti-inflammatory agent (Selective COX-2 inhibitor)) 

Sales of Celecox increased 18.4%, to ¥44.3 billion. This product has shown steady sales growth, following the acquisition of approvals for additional indications of lum- bago and acute pain on top of the indications of rheuma- toid arthritis and osteoarthritis. We further strengthened the reputation of Celecox as an anti-inflammatory that causes minimal gastrointestinal tract disturbance, capitalizing on the revision of prescribing information to reflect the results of post-marketing clinical trials, along with the “Clinical Guidelines for the Management of Low Back Pain,” issued in October 2012 by the Japanese Orthopaedic Association. In fiscal 2013, the market for anti-inflammatory agents in Japan was worth approximately ¥88.0 billion, up 3.8% from the previous fiscal year. The market share of Celecox grew steadily to around 55% (on a value basis). Astellas will continue co-promoting this drug with Pfizer Japan Inc. while targeting an even higher share of the oral anti-inflammatory market. 

## Symbicort (Treatment for adult bronchial asthma and chronic obstructive pulmonary disease) 

Sales of Symbicort, which is a combination drug of an inhaled corticosteroid and a rapid and long-acting beta-2 agonist, registered favorable growth of 28.5%, to ¥35.6 billion. Additional approval for this drug was obtained in June 2012 for new dosage and administration on an as- needed basis for reliever therapy in addition to maintenance therapy for adult bronchial asthma. Approval for Symbicort was also acquired in August 2012 for the additional indica- tion of chronic obstructive pulmonary disease. Symbicort’s sales in fiscal 2013 expanded significantly thanks to these additional indications along with growth in the combination drug market. The market in Japan for adult inhaled steroid treatment including combination drugs grew 12.5% year on year to approximately ¥105.0 billion in fiscal 2013. Symbicort also steadily grew its share of this market to around 37% (on a value basis). The dissemination of guidelines on con- trolling and preventing asthma and activities to raise public awareness of this condition has contributed to annual growth of the market for combination drugs. Astellas will continue co-promoting Symbicort with AstraZeneca K.K. in Japan to achieve further market penetration. 

